April 4, 2007 -- Roche will pay $21.50 per share or $600 million to buy research tool maker BioVeris; pSivida entered a drug delivery collaboration with Pfizer worth up to $165 million; ImClone and Bristol-Myers Squibb reported positive results from a first-line use of Erbitux in patients with head and neck cancer; Pharmacyclics filed its request for approval of a cancer drug over protest; CytRx announced positive preclinical data for arimoclomol as a stroke treatment; Genzyme and Bayer have asked for an OK of Campath as a first-line therapy for leukemia; Eurand said Zentase showed efficacy as a treatment for Exocrine Pancreatic Insufficiency; and Icagen fell after announcing it would discontinue a test of senicapoc for sickle cell disease. The Centient Biotech 200™ rose 20 points to 3948, an increase of .51%. More details...
